A Japan-based drug manufacturer won’t be required to alter its allocation of a scarce pain treatment drug to fulfill its contracts with an American drug distributor, Vice Chancellor Sam Glasscock III has ruled.

There would have been no way to enforce Takeda Pharmaceuticals’ compliance with an injunction requested by AbbVie Endocrine Inc., Glasscock wrote in a post-trial opinion.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]